Cargando…

Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid

Introduction: In recent research, orally administered cannabidiol (CBD) showed a relatively high incidence of somnolence in a pediatric population. Previous work has suggested that when CBD is exposed to an acidic environment, it degrades to Δ(9)-tetrahydrocannabinol (THC) and other psychoactive can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merrick, John, Lane, Brian, Sebree, Terri, Yaksh, Tony, O'Neill, Carol, Banks, Stan L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576596/ https://www.ncbi.nlm.nih.gov/pubmed/28861485 http://dx.doi.org/10.1089/can.2015.0004

Ejemplares similares

Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. DOI: 10.1089/can.2016.0036
por: Bonn-Miller, Marcel O., et al.
Publicado: (2017)

A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
por: Heussler, Helen, et al.
Publicado: (2019)

Psychoactive Drugs and Quality of Life
por: Ventegodt, Soren, et al.
Publicado: (2003)

Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial
por: O’Brien, Terence J., et al.
Publicado: (2022)

Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment
por: Palumbo, Joseph M., et al.
Publicado: (2023)

Evaluation of cannabidiol’s inhibitory effect on alpha-glucosidase and its stability in simulated gastric and intestinal fluids
por: Ma, Hang, et al.
Publicado: (2021)

Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial
por: Scheffer, Ingrid E., et al.
Publicado: (2021)

Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?
por: Martínez, Vicente, et al.
Publicado: (2020)

New psychoactives within polydrug use trajectories—evidence from a mixed‐method longitudinal study
por: Higgins, Kathryn, et al.
Publicado: (2021)

Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells
por: Kozela, Ewa, et al.
Publicado: (2015)

Degradation Profiling of Nardosinone at High Temperature and in Simulated Gastric and Intestinal Fluids
por: Xue, Bian-Xia, et al.
Publicado: (2023)

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2022)

Cannabidiol modulation of hippocampal glutamate in early psychosis
por: O’Neill, Aisling, et al.
Publicado: (2021)

Potential Psychoactive Effects of Microalgal Bioactive Compounds for the Case of Sleep and Mood Regulation: Opportunities and Challenges †
por: McCarthy, Bozena, et al.
Publicado: (2022)

The effect of enzymes on the in vitro degradation behavior of Mg alloy wires in simulated gastric fluid and intestinal fluid
por: Zhang, Yue, et al.
Publicado: (2021)

Characterizing the degradation of cannabidiol in an e-liquid formulation
por: Schwarzenberg, Adrián, et al.
Publicado: (2022)

Influence of Enzymes on the In Vitro Degradation Behavior of Pure Zn in Simulated Gastric and Intestinal Fluids
por: Wang, Manli, et al.
Publicado: (2022)

Worldwide legislative challenges related to psychoactive drugs
por: Negrei, Carolina, et al.
Publicado: (2017)

In Silico Investigations into the Selectivity of Psychoactive and New Psychoactive Substances in Monoamine Transporters
por: Botha, Michelle J., et al.
Publicado: (2022)

Psychoactive drugs and driving
por: Parekh, Vanita
Publicado: (2019)

Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect
por: Solinas, Marta, et al.
Publicado: (2013)

In vitro physiological and antibacterial characterization of ZnO nanoparticle composites in simulated porcine gastric and enteric fluids
por: Barreto, Marina S.R., et al.
Publicado: (2017)

Novel Psychoactive Substances: The Razor’s Edge between Therapeutical Potential and Psychoactive Recreational Misuse
por: Correia, Beatriz, et al.
Publicado: (2022)

Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model
por: Eeswara, Anjalika, et al.
Publicado: (2023)

Psychoactive Medication and Traffic Safety
por: Verster, Joris C., et al.
Publicado: (2009)

Editorial: Novel Psychoactive Drugs
por: Fattore, Liana, et al.
Publicado: (2019)

Psychoactive Drugs in Plastic Surgery
por: Davison, Steven P., et al.
Publicado: (2017)

Toxicology and Analysis of Psychoactive Tryptamines
por: Malaca, Sara, et al.
Publicado: (2020)

Psychoactive Prescribing in Assisted Living
por: Zimmerman, Sheryl, et al.
Publicado: (2020)

ANALYTICALLY CONFIRMED PRESENCE OF PSYCHOACTIVE SUBSTANCES, ESPECIALLY NEW PSYCHOACTIVE SUBSTANCES IN A GROUP OF PATIENTS HOSPITALIZED WITH MENTAL AND BEHAVIOURAL DISORDERS DUE TO THE USE OF PSYCHOACTIVE SUBSTANCES DIAGNOSIS
por: Engelgardt, Piotr, et al.
Publicado: (2022)

S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS
por: O’Neill, Aisling, et al.
Publicado: (2018)

Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial
por: Sahinovic, Ayshe, et al.
Publicado: (2022)

Cannabidiol promotes apoptosis via regulation of XIAP/Smac in gastric cancer
por: Jeong, Soyeon, et al.
Publicado: (2019)

Les vacuoles: une menace en l’air?
por: Yaksh, Tony L.
Publicado: (2010)

Frontiers in Pain Research: A Scope of Its Focus and Content
por: Yaksh, Tony L.
Publicado: (2020)

Novel Psychoactive Substances and Behavioral Addictions
por: Martinotti, Giovanni, et al.
Publicado: (2014)

Editorial: Pharmacology of new psychoactive substances
por: Lutfy, K., et al.
Publicado: (2023)

Correlation between Blood and Oral Fluid Psychoactive Drug Concentrations and Cognitive Impairment in Driving under the Influence of Drugs
por: Busardò, Francesco Paolo, et al.
Publicado: (2018)

Cannabidiol and Cannabidiol Metabolites: Pharmacokinetics, Interaction with Food, and Influence on Liver Function
por: Abbotts, Kieran Shay Struebin, et al.
Publicado: (2022)

Understanding Cannabinoid Psychoactivity with Mouse Genetic Models
por: Mackie, Ken
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ql1p1chhevr5gmdpgnqjsv96q7